Short Interest in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) Decreases By 25.8%

Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) saw a significant decrease in short interest in September. As of September 30th, there was short interest totalling 853,700 shares, a decrease of 25.8% from the September 15th total of 1,150,000 shares. Based on an average daily volume of 2,150,000 shares, the days-to-cover ratio is presently 0.4 days.

Separately, HC Wainwright reissued a “buy” rating and issued a $3.50 price objective on shares of Diffusion Pharmaceuticals in a research note on Wednesday, August 12th.

NASDAQ DFFN traded up $0.02 during midday trading on Friday, hitting $0.84. 488,044 shares of the company traded hands, compared to its average volume of 4,178,601. The company has a market cap of $53.98 million, a PE ratio of -0.48 and a beta of 1.22. The company’s 50-day simple moving average is $0.88 and its 200-day simple moving average is $0.90. Diffusion Pharmaceuticals has a 52 week low of $0.21 and a 52 week high of $1.60.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last announced its earnings results on Monday, August 10th. The company reported ($0.06) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.06). As a group, research analysts anticipate that Diffusion Pharmaceuticals will post -0.2 EPS for the current year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in Diffusion Pharmaceuticals during the 2nd quarter valued at $57,000. Jane Street Group LLC bought a new stake in Diffusion Pharmaceuticals during the 2nd quarter valued at $113,000. Finally, HCR Wealth Advisors bought a new stake in Diffusion Pharmaceuticals during the 2nd quarter valued at $38,000. 8.24% of the stock is currently owned by institutional investors and hedge funds.

About Diffusion Pharmaceuticals

Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.

Featured Article: Why is momentum important to successful trading?

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with's FREE daily email newsletter.